Impaired CD25 expression and soluble CD25-IL-2Rα receptor release by anti-CD3 stimulated peripheral blood mononuclear cells in Hodgkin's disease patients

Archivum Immunologiae et Therapiae Experimentalis

Volumn 44, Issue 2-3, 1996, Pages 127-130

  Frydecka, Irena ^a   Mazur, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Anti CD3; Hodgkin's disease; Soluble interleukin 2 receptor

Indexed keywords

CD3 ANTIGEN; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOSYNTHESIS; CHEMISTRY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; DOWN-REGULATION; FEMALE; HODGKIN DISEASE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2;

EID: 0030344525     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. AMBROSETTI A., NADALI G., VINANTE F., CARLINI S., VENERI D., TODESCHINI G., MOROSATO L., DE SABATA D., CHILOSI M., MAGGI E., PARRONCHI P., ROMAGNANI S., SEMENZATO G., PERONA G. and PIZZOLO G. (1993): Serum levels of soluble interleukin 2 receptor in Hodgkin's diseases. Cancer, 72, 201-207.
2. CARBONE P. P., KAPLAN H. S., MUSSHOFF K., SMITHERS D. W. and TUBIANA M. (1971): Report of the Committee of Hodgkin's Disease Staging Classification. Cancer Res., 31, 1860-1866.
3. CASE D. C., HANSEN J. A., CORRALES E., YOUNG C. W., DUPONT B., PINSKY C. M. and GOOD R. A. (1976): Comparison of multiple in vivo and in vitro parameters in untreated patients with Hodgkin's disease. Cancer, 38, 1807-1813.
4. CHOPRA R. K., POWERS D. C., KENDIG N. E., ABLER W. H. and NAGEL J. E. (1989): Soluble interleukin 2 receptors released from mitogen stimulated human peripheral blood lymphocytes bind interleukin 2 and inhibit IL-2 dependent cell proliferation. Immunol. Invest., 18, 961-973.
5. ELLIS P. A., HART D. N., COLLS B. M., NIMMO J. C., MAC DONALD J. E. and ANGUS H. B. (1992): Hodgkin's cells express a novel pattern of adhesion molecules. Clin. Exp. Immunol., 90, 117-123.
6. ENBLAD G., SUNDSTROM S., GRONOWITZ S. and GLIMELIUS B. (1995): Serum levels of interleukin 2 receptor (CD25) in patients with Hodgkin's disease, with special reference to age and prognosis. Ann. Oncol., 6, 65-70.
7. FRYDECKA I. (1985): Natural killer cell activity during the course of disease in patients with Hodgkin's disease. Cancer, 56, 2799-2803.
8. FRYDECKA I. and KULICZKOWSKI K. (1991): The soluble interleukin 2 receptor: a new humoral marker in hematological malignancies. Acta Haematol. Pol., 22, 327-334.
9. HOLM G., MELLSTEDT H., BJORKKHOLM M., JOHANSSON B., KILLANDER D. and SODENBERG G. (1976): Lymphocyte abnormalities in untreated patients with Hodgkin's disease. Cancer, 37, 751-757.
10. HSU S. M., TSENG C. K. and HSU P. L. (1990): Expression of p55 (Tac) interleukin 2 receptor (IL-2R), but not p75 IL-2R, in cultured H-RS cells and h-RS cells tissues. Am. J. Pathol., 136, 735-744.
11. JOSHI N. N., MUKHOPADHYAY R., ADVANI S. H. and GANGAL S. G. (1987): Production of interleukin 2 and expression of Tac antigen in Hodgkin's disease. Cancer Detect. Prev., 10 (suppl. 1), 137-143.
12. LEVY R. and KAPLAN H. S. (1974): Impaired lymphocyte function in untreated Hodgkin's disease. N. Engl. J. Med., 290, 1817-1823.
13. LIBERATI A. M., BALLATORI E., FIZOTTI M., SCHIPPA M., PROIETII M. G., DI MARZIO R., PECCI A., BISCETTI L., SBARETTI R., CLINI L. and GRIGNANI F. (1987): Immunologic profile in patients with Hodgkin's disease in complete remission. Cancer, 59, 1906-1913.
14. LOUGHMAN M. S. and NOSSAL J. V. (1990): A regulatory role for the soluble IL-2 receptor via competition with the p75 cell-surface form of the receptor for IL-2. J. Mol. Cell. Immunol., 4, 307-316.
15. MOGHE M. V., ADVANI S. H. and GANGAL S. G. (1980): Demonstration of inhibitory factors affecting cell-mediated immunity in patients with Hodgkin's disease. Eur. J. Cancer, 16, 937-944.
16. MANGGE H., BEAUFORT A., NEUBAUER M., SAMITZ M. and SCHAUENSTEIN K. (1990): Peripheral blood lymphocytes of nonleukemic lymphoma patients exhibit aberrant expression of T-cell activation markers after polyclonal stimulation in vitro. Cancer, 66, 677-685.
17. NAKAGOMI H., PETERSSON M., MAGUSSON I., JUHLIN C., MATSUDA M., MELLSTED H., TAUPJN J. L., VIVIER E., ANDERSON P. and KIESSLING R. (1993): Decreased expression of the signal-trasducing zeta chains in tumor-intrafiltrating T cells and NK cells of patients with colorectal carcinoma. Cancer Res., 53, 5610-5612.
18. NELSON D. I., KURMAN C. C., FRITZ M. E., BOUTIN B. and RUBIN L. A. (1986): The production of soluble and cellular interleukin 2 receptors by cord blood mononuclear cells following in vitro activation. Pediatr. Res., 20, 136-139.
19. PIZZOLO G., CHILOSI M., SEMENZATO G., CALIGARIS-CAPPIO F., FIORE-DONATI L., PERONA G. and JANOSSY G. (1984): Immunohistological analysis of Tac antigen expression in tissues involved by Hodgkin's disease. Br. J. Cancer, 50, 415-417.
20. PIZZOLO G., VICENZI C, VIVANTE F., RIGO A., VENERI D., CHILOSI M., DISI S., POLI G., ZAMBELLO R., SEMENZATO G. and BERTONI G. (1993): Highly concentrated urine-purified Tac peptide fail to inhibit IL-2 dependent cell proliferation. Cell. Immunol., 141, 253-260.
21. PIZZOLO G., VINANTE F., NADALI G., RICETTI M. M., MOROSATO L., MARROCHELLA R., VICENZI C, SEMENZATO G, and CHILOSI M. (1993): ICAM-1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin's disease. Br. J. Haematol., 84, 161-162.
22. PUI C. H., IP S. H., THOMPSON E., WILIAMS J., BROWN M., DODGE R. K., DE HOYOS L. A., BERARD C. W. and CRIST W. M. (1989): High, serum interleukin 2 receptor levels correlate with poor prognosis in children with Hodgkin's disease. Leukemia, 3, 481-484.
23. RUBIN L. A., KURMAN C. C., FRITZ M. E., BIDDOSON W. E., BOUTIN B., YARCHOAN R. and NELSON D. L. (1985): Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol., 135, 3172-3177.
24. RUCO L. P., POMPONI D., PIGOTT R., GEARING A. J., BAIOCCHINI A. and BARONI C. D. (1992): Expression and cell distribution of the intercellular adhesion molecule, vascular cell adhesion molecule, endothelial leukocyte adhesion molecule, and endothelial cell adhesion molecule (CD31) in reactive human lymph nodes and in Hodgkin's disease. Am. J. Pathol., 140, 1337-1344.
25. SCHULOF R. S., LACHER M. J. and GUPTA S. (1981): Abnormal phytohemagglutinin-induced T cell proliferative responses in Hodgkin's disease. Blood, 57, 607-609.
26. SHEIBANI K., WINBERG C. D., VANDE VELDE S., BLAYNEI D. W. and RAPPAPORT H. (1987): Distribution of lymphocytes with interleukin 2 receptors (Tac antigen) in reactive lymphoproliferative processes. Hodgkin's disease and non-Hodgkin's lymphomas an immunohistologic study of 300 cases. Am. J. Pathol., 127, 27-37.
27. SINCLAIR T., EZDINLI E. Z., BOONLAYANGOOR P., WASSER L. P. and HAN T. (1983): Rosette and blastogenesis inhibition by plasma from Hodgkin's disease and other malignancies. Positive correlation in stage I and II Hodgkin's disease. Cancer, 51, 238-242.
28. SUGDEN P. J. and LILLEYMAN J. S. (1980): Impairment of lymphocyte transformation by plasma from patients with advanced Hodgkin's disease. Cancer, 45, 899-906.
29. TAX W. J., HERMES F. F. M., WILLEMS R. K., CAPEL J. A. and KOENE R. A. P. (1984): Fc receptors for mouse IgG1 on human monocytes: polymorphism and role in antibody induced proliferation. J. Immunol., 133, 1185-1189.
30. TREIGER G., LEONARD W. J., SRETLIK P., RUBIN L. A., NELSON D. I. and GREENE W. C. (1986): A secreted form of the human interleukin 2 receptor encoded by an anchor minus cDNA. J. Immunol., 136, 4099-4108.
31. WEISS A., WISCOCIL R. I. and STOBO J. D. (1984): The role of T3 surface molecules in the activation of human T cells: a two stimulus requirement for IL-2 production reflects events occuring at a pre-translational level. J. Immunol., 133, 123-128.
32. ZAMKOFF K. W., REEVES W. G., PAOLOZZI F. P., POIESZ B. J., COMIS R. I. and TOMAR R. H. (1985): Impaired interleukin regulation of the phytohemagglutinin response in Hodgkin's disease. Clin. Immunol. Immunopathol., 35, 111-119.